The M&A hunt is on — here are the prime targets

Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

By Kelly Bilodeau • Jan. 17, 2023

Pro sports’ COVID protocols led to real-world data impacts for pharma

After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

By Karissa Waddick • Jan. 16, 2023

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

How biotechs can weather the market storm

Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

By Meagan Parrish • Jan. 13, 2023

Space — the next frontier in drug development

Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

By Kelly Bilodeau • Jan. 12, 2023

Biopharma M&A may get the push it needs in 2023, but with a face lift

A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

By Michael Gibney • Jan. 12, 2023

Woman of the Week: Form Bio’s Claire Aldridge

The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

By Taren Grom • Jan. 11, 2023

C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

By Karissa Waddick • Jan. 10, 2023

The kindred nature of martial arts and drug development

How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

By Alexandra Pecci • Jan. 9, 2023

What’s top of mind for industry execs at JPM?

Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

By Taren Grom • Jan. 6, 2023

A new mission in menopause — extending the lives of women

Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.

By Meagan Parrish • Jan. 5, 2023

Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

By Michael Gibney • Jan. 5, 2023

Nonprofits are bridging R&D’s valley of death

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

By Kelly Bilodeau • Jan. 4, 2023

Forks in the road lead one medical expert to a ‘game changing’ liver treatment

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

By Alexandra Pecci • Jan. 3, 2023

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

From chemistry to canvas: What the pharma world can learn from art

Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work. 

By Karissa Waddick • Dec. 22, 2022

WoW: What a year

A look back at some of the most inspirational quotes from the Women of the Week podcasts in 2022.

By Taren Grom • Dec. 20, 2022

With mpox cases mysteriously dwindling, scientists search for answers

Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.

By Kelly Bilodeau • Dec. 19, 2022

Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.

By Michael Gibney • Dec. 19, 2022

Can pharma quit Twitter? Social strategy evolves as Musk changes the platform

A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.

By Karissa Waddick • Dec. 16, 2022

At the heart of hematology breakthroughs, a community of researchers and patients comes together

As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.

By Michael Gibney • Dec. 13, 2022

The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022

The pharma giants making the biggest strides with global drug access

A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.

By Kelly Bilodeau • Dec. 12, 2022

Spotlight on oncology drug development & its future

Learn why an informed, holistic view is needed to succeed in today’s complex and dynamic landscape.

Dec. 12, 2022

Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

By Taren Grom • Dec. 9, 2022

Takeda’s global quest for health equity

Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

By Taren Grom • Dec. 8, 2022